Holen Sie sich die Stockscreener-App
4.76
3.94%
-0.195
Handel nachbörslich:
4.76
Schlusskurs vom Vortag:
$4.955
Offen:
$4.92
24-Stunden-Volumen:
1.06M
Relative Volume:
0.91
Marktkapitalisierung:
$257.95M
Einnahmen:
$400.00K
Nettoeinkommen (Verlust:
$82.35M
KGV:
4.0848
EPS:
1.1653
Netto-Cashflow:
$-82.36M
1W Leistung:
-1.86%
1M Leistung:
-4.99%
6M Leistung:
-25.97%
1J Leistung:
-9.85%
1-Tages-Spanne:
$4.73
$5.02
1-Wochen-Bereich:
$4.73
$5.32
52-Wochen-Spanne:
$3.9328
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Firmenname
Abeona Therapeutics Inc
Sektor
Branche
Telefon
646-813-4701
Adresse
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
4.76 | 268.52M | 400.00K | 82.35M | -82.36M | 1.1653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-03-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-30 | Eingeleitet | Stifel | Buy |
| 2020-11-11 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-02-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-12-10 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2019-08-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2019-08-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-06-27 | Eingeleitet | Mizuho | Buy |
| 2018-10-12 | Eingeleitet | Mizuho | Buy |
| 2018-06-05 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-11-08 | Eingeleitet | SunTrust | Buy |
| 2017-10-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-10-10 | Eingeleitet | Citigroup | Buy |
| 2017-10-05 | Bestätigt | Maxim Group | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-18 | Bestätigt | Maxim Group | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-01-06 | Eingeleitet | Jefferies | Buy |
| 2016-09-29 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Abeona Therapeutics Inc Aktie (ABEO) Neueste Nachrichten
Abeona Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Abeona reports progress in ZEVASKYN gene therapy launch - Investing.com Nigeria
Q4 EPS Forecast for Abeona Therapeutics Increased by Analyst - MarketBeat
HC Wainwright Has Bullish Outlook for ABEO FY2025 Earnings - MarketBeat
Abeona Therapeutics Says ZEVASKYN Launch Is Back on Track, Eyes Profitability in 2026 - MarketBeat
Abeona Therapeutics at Leerink Global Healthcare Conference: Strategic Launch Insights - Investing.com Canada
HC Wainwright Reaffirms "Buy" Rating for Abeona Therapeutics (NASDAQ:ABEO) - MarketBeat
Abeona Therapeutics (ABEO) Receives Consistent Analyst Rating of "Buy" | ABEO Stock News - GuruFocus
Oppenheimer Maintains Outperform on Abeona Therapeutics (ABEO) PT $22 March 2026 - Meyka
Oppenheimer raises Abeona Therapeutics price target on launch progress - Investing.com
Abeona Therapeutics Announces Momentum in ZEVASKYN® Gene Therapy Launch for Recessive Dystrophic Epidermolysis Bullosa (RDEB) - Minichart
Abeona Therapeutics (ABEO) Progress with Zevaskyn Launch - GuruFocus
Abeona Accelerates ZEVASKYN Commercial Momentum and Market Access - TipRanks
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch - The Manila Times
Abeona Therapeutics reports early commercial momentum and payer coverage for ZEVASKYN launch - TradingView
Gene therapy ZEVASKYN gains broad insurance coverage for RDEB patients - Stock Titan
Abeona Therapeutics Announces Date of Fourth Quarter, Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference - marketscreener.com
Abeona Therapeutics Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference - 富途牛牛
Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference - marketscreener.com
Avoiding Lag: Real-Time Signals in (ABEO) Movement - Stock Traders Daily
Abeona Therapeutics Inc. $ABEO Shares Sold by Western Standard LLC - MarketBeat
Abeona Therapeutics Inc. (ABEO) Stock Analysis: Exploring a Potential 289% Upside in Gene Therapy Innovations - DirectorsTalk Interviews
Abeona Therapeutics (NASDAQ:ABEO) Stock Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Vanda (VNDA), Abeona Therapeutics (ABEO) - The Globe and Mail
Is Abeona Therapeutics Inc. a strong growth stockInflation Watch & Safe Entry Momentum Tips - mfd.ru
Big Picture: Does Abeona Therapeutics Inc have strong EBITDA marginsJuly 2025 EndofMonth & Safe Entry Zone Tips - baoquankhu1.vn
Discipline and Rules-Based Execution in ABEO Response - Stock Traders Daily
Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Epidermolysis Bullosa Clinical Trial Pipeline Robust as 20+ - openPR.com
Is Abeona Therapeutics Inc. (PCJ) stock undervalued by metricsJuly 2025 Price Swings & Low Drawdown Trading Strategies - mfd.ru
Published on: 2026-02-14 07:33:27 - mfd.ru
ABEO SEC FilingsAbeona Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Is Abeona Therapeutics Inc. stock overvalued or fairly priced2025 Buyback Activity & Fast Moving Stock Watchlists - mfd.ru
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Seven new Abeona hires get 3-year stock grants as inducement - Stock Titan
Behavioral Patterns of ABEO and Institutional Flows - Stock Traders Daily
Abeona Therapeutics Inc. (ABEO) Investor Outlook: Unpacking A 306% Potential Upside - DirectorsTalk Interviews
Abeona Therapeutics (NASDAQ:ABEO) Director Sells 20,070 Shares - MarketBeat
Abeona sells Rare Pediatric Disease PRV for $155M - MSN
Abeona Therapeutics director sells $75k in stock - Investing.com India
Abeona Therapeutics director sells $75k in stock By Investing.com - Investing.com South Africa
Crombez Eric sells Abeona Therapeutics (ABEO) shares for $82895 By Investing.com - Investing.com Nigeria
Crombez Eric sells Abeona Therapeutics (ABEO) shares for $82895 - Investing.com
Abeona Therapeutics (NASDAQ:ABEO) Director Eric Crombez Sells 16,284 Shares - MarketBeat
Abeona Therapeutics (NASDAQ:ABEO) Director Mark Alvino Sells 2,000 Shares - MarketBeat
Leila Alland Sells 18,065 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock - MarketBeat
Insider-Favored Growth Companies To Watch February 2026 - simplywall.st
Merger Talk: Is Abeona Therapeutics Inc in a bullish channelSwing Trade & Stock Timing and Entry Methods - baoquankhu1.vn
Sentiment Watch: How does FVNNU score in quality rankingsBond Market & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Dividend Watch: How does CBTJ correlate with NasdaqWeekly Gains Summary & Accurate Buy Signal Notifications - baoquankhu1.vn
Is Abeona Therapeutics Inc. stock forming a cup and handleJuly 2025 Highlights & Reliable Volume Spike Alerts - mfd.ru
Finanzdaten der Abeona Therapeutics Inc-Aktie (ABEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):